Resultado de búsqueda
Hace 2 días · We all say overall survival [OS], but if you look at the OS, the trial outcomes don’t show [significant benefit vs sunitinib in favorable-risk patients]. So what do you consider in your practice?
Hace 3 días · In this investigator-initiated trial, the TROP-2–targeted antibody-drug conjugate sacituzumab govitecan was evaluated in combination with ipilimumab and nivolumab in patients with...
Hace 2 días · Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a...
Hace 5 días · DrugPatentWatch employs three methods to identify biologic patents: Brand-side disclosures in response to biosimilar applications. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry.
Hace 11 horas · Patients treated with Opdivo plus Yervoy maintained superior survival and more durable response benefits compared to those who received sunitinib in both patients with intermediate- and poor-risk prognostic factors and across all randomized patients.
Hace 4 días · Evkeeza® is an injectable prescription medicine used along with other low-density lipoprotein (LDL) lowering medicines in people 5 years of age and older with a type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). For more information, visit the patient website for this drug.
Hace 3 días · MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable
